Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 1:07 PM
Ignite Modification Date: 2025-12-25 @ 12:21 PM
NCT ID: NCT03636061
Description: None
Frequency Threshold: 0
Time Frame: Adverse Events were collected from the first dose of study drug administration until the final study visit at Visit 5 (28 days)
Study: NCT03636061
Study Brief: Evaluation of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
OC-01 Low Dose, 0.12 mg/mL OC-01 0.12 mg/ml nasal spray 0 None 0 47 33 47 View
OC-01 Mid Dose, 0.6 mg/mL OC-01 0.6 mg/ml nasal spray 0 None 1 48 44 48 View
OC-01 High Dose, 1.2 mg/mL OC-01 1.2 mg/ml nasal spray 0 None 0 44 41 44 View
Placebo Vehicle nasal spray 0 None 0 43 11 43 View
Serious Events(If Any):

Serious Events

Term Type Organ System Vocab View
Anaemia SYSTEMATIC_ASSESSMENT Blood and lymphatic system disorders MedDRA (20.1) View
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Conjunctival deposit SYSTEMATIC_ASSESSMENT Eye disorders MedDRA (20.1) View
Visual impairement SYSTEMATIC_ASSESSMENT Eye disorders MedDRA (20.1) View
Cough SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (20.1) View
Nasal dryness SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (20.1) View
Ocular TEAEs SYSTEMATIC_ASSESSMENT Eye disorders MedDRA (20.1) View
Visual acuity reduced SYSTEMATIC_ASSESSMENT Eye disorders MedDRA (20.1) View
Blepharospasm SYSTEMATIC_ASSESSMENT Eye disorders MedDRA (20.1) View
Conjunctival haemorrhage SYSTEMATIC_ASSESSMENT Eye disorders MedDRA (20.1) View
Eyelid oedema SYSTEMATIC_ASSESSMENT Eye disorders MedDRA (20.1) View
Hordeolum SYSTEMATIC_ASSESSMENT Eye disorders MedDRA (20.1) View
Sneezing SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (20.1) View
Throat irritation SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (20.1) View
Dysaesthesia pharynx SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (20.1) View
Instillation site irritation SYSTEMATIC_ASSESSMENT General disorders MedDRA (20.1) View
Headache SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (20.1) View